Biomarker assay to enable safe corticosteroid withdrawal

submit enquiry
Cards carried to avoid the risk of over-treatment of steroids
Cards carried to avoid the risk of over-treatment of steroids

University: University of Edinburgh

Sector(s): Healthcare & Pharmaceuticals, Life Sciences

About Opportunity:

The Challenge

Corticosteroids are the 2nd most commonly prescribed class of drugs, behind NSAIDs, and are used for a wide range of inflammatory conditions. However, they have numerous side-effects, including adrenal insufficiency (AI), even for low dose corticosteroids. Diagnosing AI is difficult and expensive, and relies on the SynACTHen test, which is not routinely performed, leading to substantial under-diagnosis of AI. Pharmacokinetic monitoring of corticosteroids is unreliable, and no pharmacodynamic test exists to detect corticosteroid side effects. A pharmacodynamic test would also be useful for dose adjustment in patients receiving corticosteroid replacement therapy and for screening in patients with suspected Cushing’s syndrome.


Seven key biomarkers have been identified from metabolomics screening of patient samples. These biomarkers are measured using standard LC-MS techniques and can provide pharmacodynamic information of corticosteroid over-treatment from patient samples. This allows optimization of the corticosteroid dose regime for each patient, prediction of adverse effects of overtreatment, including adrenal insufficiency, and improvement of the diagnosis of Cushing’s syndrome.

Exemplification Data

Using LC-MS metabolomic screening on plasma samples from 117 individuals with congenital adrenal hyperplasia (taking known doses of corticosteroids), the analysis demonstrated a clear cut-off in dose-response relationships, such that the metabolome distinguished doses above or below the equivalent of 5 mg of prednisolone each day (the physiological replacement dose).

Key Benefits:

  • A simple alternative to the relatively insensitive and time-consuming assays currently in use, e.g. SynACTHen test
  • Can be developed into a ‘kit assay’ for clinical use
  • Ability to carry out testing at most clinical labs due to the common use of LC-MS


  • Medical devices
  • Diagnostic assay kit

IP Status:

Early stage laboratory data. Priority filing stage.


Please enter your name.

Please enter the name of the company you work for.

Is your company an SME?

Please select the country you are in.

Please select what part of the UK you are in.

Please select from the following options.

Please enter your email address.

To help us process your enquiry faster please enter some details about the information you are interested in.

Words remaining:

Related Opportunities

  • Telomerase Promoter - Cancer Therapies

    The University of Glasgow has developed a (Ad-hTR-NTR) which has been extensively tested on Ovarian cancer cells.

    Expires: Created:
  • SNP-based assay for analysis of MRSA

    This assay is a rapid and reproducible approach for epidemiological analysis of methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates. The assay identifies different strains on EMRSA-15, which is a major cause of hospital acquired MRSA infections in the UK and in other parts of the wo...

    Expires: Created:
  • Catanostics - Non-Invasive Early Stage Cataract Diagnosis & Severity Quantification tool

    Catanostics (Cataract Diagnostics) offers an alternative to the slit lamp currently used for cataract diagnosis before referring a patient for cataract surgery. Our non-invasive fluorescence scan offers "better diagnosis" through non-subjective analysis of data on cataract symptoms & severity lea...

    Expires: Created:
  • Transforming Pharmaceutical Crystal Forms

    The innovation provides a gas-induced method for phase-transforming organic solids, such as pharmaceutical crystals. The inventive method subjects the polymorphs of pharmaceutical agents to various pressures of gases (such as CO2, N2O, and CH4) to induce phase transform with ease.

    Expires: Created:
  • Sperm Motility Enhancers for Assisted Reproductive Technology

    Sperm Motility Enhancers: A Novel Strategy for Assisted Reproductive Technology (ART) based on the direct relationship between human fertility and sperm motility,the University of Dundee has successfully identified FDA-approved compounds with robust and effective stimulation on patient sperm motilit...

    Expires: Created:

Alerts Signup

Sign up to our technology alerts and be the first to hear about any new technology opportunities from Scotland's universities

Register Now for University Alerts

Search Filter

Share this page

Use the buttons below to share these technology opportunities on your favourite social networking site. You can also share them from inside the individual opportunity.